Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Austria.
Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Austria; Department of Medicine, Division of Hematology and Oncology, Thrombosis and Hemostasis Program, UNC McAllister Heart Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Thromb Res. 2017 Jul;155:131-139. doi: 10.1016/j.thromres.2017.05.013. Epub 2017 May 13.
Hemophilia A and B are inherited bleeding disorders due to deficiencies of the clotting factors VIII and IX, respectively. The severity of the disease correlates with remaining factor levels, although individual differences in bleeding tendency are seen despite similar factor levels. While thrombin generation is severely impaired in persons with hemophilia, primary hemostasis, i.e. platelet function, has been generally considered to be normal. However, some studies reported prolonged bleeding times in hemophilia, suggesting that also primary hemostasis is affected. In several other studies different aspects of platelet function in hemophilia have been investigated in more detail and various alterations were discovered, such as increased platelet P-selectin expression, a lower number of procoagulant, so-called 'coated' platelets, lower aggregation upon co-incubation with tissue factor, or reduced platelet contractile forces during clot formation in comparison to healthy individuals. An influence of platelet function on clinical phenotype was suggested, which might contribute in part to variations in bleeding tendency in hemophilic patients with similar factor levels. However, the available evidence is currently limited and no clear correlations between platelet function parameters and clinical phenotypes have been demonstrated. The impact of alterations of platelet function in hemophilia remains to be better defined. Another interesting role of platelets in hemophilia has been reported recently by establishing a novel gene-therapeutic strategy using platelets as a delivery system for FVIII, showing promising results in animal models. This review gives an overview on the currently published literature on platelet function and the potential roles of platelets in hemophilia.
A 型和 B 型血友病分别是由于凝血因子 VIII 和 IX 的缺乏而引起的遗传性出血性疾病。疾病的严重程度与剩余因子水平相关,但尽管因子水平相似,仍存在个体出血倾向的差异。尽管在血友病患者中凝血酶生成严重受损,但通常认为主要止血,即血小板功能正常。然而,一些研究报告称血友病患者出血时间延长,表明主要止血也受到影响。在其他几项研究中,更详细地研究了血友病中血小板功能的不同方面,发现了各种改变,例如血小板 P-选择素表达增加、促凝数量减少,所谓的“涂层”血小板、与组织因子共孵育时的聚集减少,或与健康个体相比,在凝块形成过程中血小板收缩力降低。有人提出血小板功能对临床表型有影响,这可能部分导致因子水平相似的血友病患者出血倾向的变化。然而,目前证据有限,尚未证明血小板功能参数与临床表型之间存在明确的相关性。血友病中血小板功能改变的影响仍有待更好地定义。最近通过建立一种使用血小板作为 FVIII 传递系统的新型基因治疗策略,在动物模型中显示出有希望的结果,报道了血小板在血友病中的另一个有趣作用。这篇综述概述了目前关于血小板功能的文献以及血小板在血友病中的潜在作用。